Clever Leaves to Receive US$11.4 Million Over Three-year Deal

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that it has entered into a three-year “take or pay” partnership agreement with Entourage Phytolab, a rapidly growing pharmaceutical cannabis research and development company in Brazil. Clever Leaves will be paid approximately US $11.4M over the term of the agreement to supply certain finished products for distribution through the pharmaceutical and the compassionate care markets in Brazil. In a second agreement, Clever Leaves will also provide active pharmaceutical ingredients (APIs) for proprietary formulations of Entourage. Supply of the finished products will commence in January 2021, with the APIs also targeting Q1 of 2021.

Entourage Phytolab, a leading research and development cannabis company with a strong reputation in Brazil, develops registered, safe and effective drugs to increase patients’ access to the therapeutic potential of cannabinoids and will use Clever Leaves’ API in its first botanical drug candidate. According to data and research company, New Frontier Data, Brazil represents the largest addressable market in Latin America with a population of 210 million and a rapidly growing patient network for medical cannabis.

“With their regulatory expertise in Brazil as well as their clinical research experience, Entourage Phytolab is an ideal partner and represents an incredible opportunity for Clever Leaves to distribute cannabinoid products throughout Brazil,” said Kyle Detwiler, CEO of Clever Leaves. “We expect our robust product development expertise and EU GMP certified facilities, which satisfy the Brazil National Health Surveillance Agency’s (ANVISA) strict quality standards, positions us to enable our partners to capitalize on growing patient demand as the Brazilian cannabis industry begins to accelerate.”

“Entourage Phytolab started its activities in 2015 and is a leader in the research and development of CBD and THC based medicines globally,” said Caio Santos Abreu, Founder and CEO of Entourage Phytolab. “After five years of R&D, we are launching our first products in 2021 and the partnership with Clever Leaves is an important step for us to build the best portfolio of cannabis-based medicines in the country.”

“This agreement expands Clever Leaves’ presence in one of the largest markets in South America as we continue to establish formidable commercial partnerships around the world,” said Andrés Fajardo, President of Clever Leaves. “Equipped with high quality products, Entourage Phytolab has the potential to reach thousands of patients across the country through their market access and capabilities, and these products will set the standard for quality and value for Brazilian patients.”

About Clever Leaves Holdings Inc.

Clever Leaves is a multi-national cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry’s leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community.  Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute – Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a provisional license in Portugal from Infarmed – the Portuguese health authority – that allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes.

For more information, please visit

About Entourage Phytolab

Founded in 2015 in Sao Paulo, Entourage Phytolab is a Brazilian biotech pioneer in the research and development of cannabis-based medicines. Entourage’s R&D team is creating a new generation of cannabinoid drugs, proprietary superior bioavailability formulations and conducting regulatory clinical trials. The first products will hit the market in 2021 and will be used to treat problems such as epilepsy, chronic pain, cancer pain, insomnia, and arthritis.

For more information, please visit